Life Science Leader Newshttps://www.lifescienceleader.com/
News Articles from Life Science LeaderWed, 21 Feb 2018 22:14:52 GMTWed, 14 Oct 2009 00:11:00 GMThttps://www.lifescienceleader.com/doc/implementing-a-supply-chain-risk-management-0001?atc~c=771+s=773+r=001+l=a Implementing A Supply Chain Risk Management Process <p>
To paraphrase a television news show catch line, &ldquo;It&rsquo;s 10 p.m. Do you know where your product is?&rdquo; Every life science executive has asked this question in one form or another. And, most of us have wondered about the answer. This becomes a much harder question to honestly answer as we grow our supply and fulfillment organizations over multiple countries in our quest to control costs and compete. <i>By Peter Blok, senior partner, Pharma Team USA</i></p>
Wed, 01 Apr 2009 00:11:00 GMThttps://www.lifescienceleader.com/doc/10-tips-for-avoiding-cmms-failure-0001?atc~c=771+s=773+r=001+l=a 10 Tips For Avoiding CMMS Failure <p>
Computerized maintenance management systems (CMMS) and enterprise asset management (EAM) systems have been longtime fixtures in other industries, embraced to improve control over asset maintenance costs and improve asset performance. <i>By Marcus McNeely, project manager, Blue Mountain Quality Resources, Inc.</i></p>
Wed, 01 Apr 2009 00:35:00 GMThttps://www.lifescienceleader.com/doc/enabling-new-and-advanced-drugs-to-come-0001?atc~c=771+s=773+r=001+l=a Enabling New And Advanced Drugs To Come To Market With Nanotechnology <p>
Many new and advanced drug (and vaccine) formulations that could effectively treat human and veterinary diseases may never make it beyond the laboratory. Three common problems exist with these drugs: a) limited bioavailability (the rate at which the active drug enters the systemic circulation, making it difficult for the body to adsorb), b) issues concerning the safe and efficient delivery of the drug into the circulatory system, and c) the toxicity level of the drug. <i>By Bob Bruno, <u>Life Science Leader</u> magazine</i></p>
Tue, 07 Apr 2009 00:17:00 GMThttps://www.lifescienceleader.com/doc/lean-not-mean-how-to-increase-your-0001?atc~c=771+s=773+r=001+l=a Lean, Not Mean: How To Increase Your Competitiveness And Maximize Profitability <p>Eliminating operational waste and optimizing production is now becoming top of mind for many biopharmaceutical executives &mdash; particularly during this difficult economic cycle. Manufacturers could yield greater profits by developing and implementing a well-established Lean manufacturing program, with significant long-term rewards. <i>By Dan Schell, <u>Life Science Leader</u> magazine</i></p>
Tue, 07 Apr 2009 00:28:00 GMTDanSchellhttps://www.lifescienceleader.com/doc/will-healthcare-reform-boost-pharma-prospects-0001?atc~c=771+s=773+r=001+l=a Will Healthcare Reform Boost Pharma Prospects In China? After a year of stunning growth in 2007, the pharmaceutical industry in China delivered another impeccable performance in 2008. Revenues of the Chinese pharmaceutical manufacturing sector rose 28.8% while its total profits jumped 39.8% in the first eight months of 2008. By James Shen, Life Science Leader magazine Tue, 07 Apr 2009 00:36:00 GMThttps://www.lifescienceleader.com/doc/integrated-service-delivery-turning-in-early-0001?atc~c=771+s=773+r=001+l=a Integrated Service Delivery Turning In Early Gains In Lab Equipment Maintenance <p>
Enveloped by current acute economic stringencies, administrators must strive even harder to reduce costs while boosting the productivity of their laboratories. To facilitate efficiency, managers traditionally tapped into four key equipment service schemes &mdash; in-house capabilities, service consolidators, outsourcing to independent service providers, and the OEM service model where the manufacturers service instruments. To be sure, each offers gains and setbacks. <i>By Bernard Tulsi, <u>Life Science Leader</u> magazine</i></p>
Wed, 15 Apr 2009 00:20:00 GMThttps://www.lifescienceleader.com/doc/good-housekeeping-the-art-of-contamination-0001?atc~c=771+s=773+r=001+l=a Good Housekeeping: The Art Of Contamination Controls <p>
It took Dr. Joseph Lister a while to convince physicians that something invisible had to be protected against, but since the concept took hold, cleanliness has been a major concern in life sciences. Now there are numerous standards defining &ldquo;clean&rdquo; in hospitals, pharmaceutical manufacturers, biotech labs, and other life sciences areas, plus numerous options for meeting those standards. <i>By Wendy Meyerhoff, <u>Life Science Leader</u> magazine</i></p>
Thu, 18 Jun 2009 00:15:00 GMThttps://www.lifescienceleader.com/doc/the-key-considerations-of-clinical-trials-0001?atc~c=771+s=773+r=001+l=a The Key Considerations Of Clinical Trials <p>
Clinical trials are only a small part of the research that goes into developing a new treatment. Drugs of the future, for example, first have to be discovered, purified, described, and tested in labs (in cell and animal studies) before ever reaching human clinical trials. About 1,000 potential drugs are tested before just one reaches the point of being tested in a clinical trial. <i>By William McGinnis, <u>Life Science Leader</u> magazine</i></p>
Thu, 18 Jun 2009 00:24:00 GMThttps://www.lifescienceleader.com/doc/india-growing-as-an-outsourcing-destination-0001?atc~c=771+s=773+r=001+l=a India Growing As An Outsourcing Destination <p>
As the current storm in global finance continues to test our defenses, it is a safer-than-usual bet that the long-range forecast for most industries will remain uncertain. <i>By Dr. R. Ananth, <u>Life Science Leader</u> magazine</i></p>
Mon, 22 Jun 2009 23:58:00 GMThttps://www.lifescienceleader.com/doc/research-efficiency-in-hard-times-its-time-0001?atc~c=771+s=773+r=001+l=a Research Efficiency In Hard Times: It's Time To Adapt <p>
Nobody likes hard times, but they do have one redeeming quality: They focus attention on areas neglected in good times. The need for greater efficiency is a prime example, especially for small drug development companies. Even in the best of times, they must cope with the formidable combination of high costs, long timelines, and low success rates. And when hard times come, they feel it first and most acutely. These companies should be the first to ask: Is there a better way? <i>By Michael Rosenberg, M.D., MPH, <u>Life Science Leader</u> magazine</i></p>
Tue, 23 Jun 2009 01:03:00 GMThttps://www.lifescienceleader.com/doc/a-view-from-the-top-qa-with-astrazeneca-ceo-0001?atc~c=771+s=773+r=001+l=a A View From The Top: Q&A With AstraZeneca CEO David Brennan <p>
In 2008, AstraZeneca helped more than 440,000 people save more than $612M on their medicines through our prescription savings programs. <i>By Dan Schell, <u>Life Science Leader</u> magazine</i></p>
Wed, 29 Jul 2009 05:18:00 GMTDanSchellhttps://www.lifescienceleader.com/doc/bring-your-oncology-drug-to-market-quicker-0001?atc~c=771+s=773+r=001+l=a Bring Your Oncology Drug To Market Quicker: Think Patients First<p>
New cancer drugs take too much time and cost too much money to bring to market. The time to peak sales for products in development can be shortened by reducing the time to complete patient enrollment. This seems to be a simple concept, yet it is difficult to accomplish in the oncology sector. <i>By Matthew Wiener, PharmD, founder and chief operating officer, Pharmatech Oncology</i></p>
Mon, 03 Aug 2009 02:38:00 GMThttps://www.lifescienceleader.com/doc/an-update-regarding-follow-on-biologics-0001?atc~c=771+s=773+r=001+l=a An Update Regarding Follow-On Biologics <p>
The debate over whether or not lower cost, &ldquo;generic&rdquo; versions of biologics and biotechnology drugs ought to be brought to market has been a very long and contentious one. However, rising healthcare costs and demands for greater access to biotechnology drugs have finally induced Congress to consider legislation to guide approval of these products. <i>By Cliff Mintz, <u>Life Science Leader</u> magazine</i></p>
Tue, 04 Aug 2009 00:45:00 GMThttps://www.lifescienceleader.com/doc/strategic-technical-intelligence-a-0001?atc~c=771+s=773+r=001+l=a Strategic & Technical Intelligence: A Prerequisite For Life Science Success <p>
Given the dynamic nature of the life sciences industry coupled with its high financial stakes, it is prudent for a pharmaceutical company to expand its market intelligence program beyond the short-term needs of management and brand teams. <i>By Bill Kelly, president and cofounder, BioInformatics LLC</i></p>
Tue, 04 Aug 2009 00:54:00 GMThttps://www.lifescienceleader.com/doc/policy-shift-on-stem-cell-research-may-0001?atc~c=771+s=773+r=001+l=a Policy Shift On Stem Cell Research May Produce Effect Overseas <p>
Some countries in Europe and elsewhere are looking ahead for opportunities that might emerge from the recent public policy change in the United States that allows federal funding of embryonic stem cell research. Industry experts expect the stem cell industry to flourish in the favorable environment they see developing. <i>By Ann Roberts Brice, <u>Life Science Leader</u> magazine</i></p>
Tue, 04 Aug 2009 01:08:00 GMThttps://www.lifescienceleader.com/doc/the-importance-of-package-testing-0001?atc~c=771+s=773+r=001+l=a The Importance Of Package Testing <p>
For more than 23 years, Tony Stauffer, president of Packaging Technologies &amp; Inspection (PTI), has focused on developing inspection technologies for the packaging industry that perform with a high degree of precision and reliability and simplify testing and validation processes in the food, pharmaceutical, medical device, and container industries. <i>By <u>Life Science Leader</u> magazine</i></p>
Thu, 03 Sep 2009 01:17:00 GMThttps://www.lifescienceleader.com/doc/the-transformation-of-sanofi-aventis-us-0001?atc~c=771+s=773+r=001+l=a The Transformation Of Sanofi-Aventis U.S. <p>The exclusive Life Science Leader interview with Gregory Irace, president and CEO of sanofi-aventis U.S. <i>By Dan Schell, <u>Life Science Leader</u> magazine</i></p>
Thu, 17 Sep 2009 23:59:00 GMTDanSchellhttps://www.lifescienceleader.com/doc/from-the-garage-to-the-biotech-fast-track-0001?atc~c=771+s=773+r=001+l=a From The Garage To The Biotech Fast Track <p>Jonathan E. Lim, M.D., came to San Diego-based Halozyme Therapeutics as CEO in 2003, when the biopharma company was &ldquo;four scientists in a garage.&rdquo; (He was employee number five.) When he started, the company had three months worth of cash. Immediately, he began seeking venture capital, and after contacting 50 VCs without any luck, the cash ran out. <i>By Alan Horowitz, <u>Life Science Leader</u> magazine</i></p>
Fri, 18 Sep 2009 00:11:00 GMThttps://www.lifescienceleader.com/doc/10-mistakes-to-avoid-when-seeking-venture-0001?atc~c=771+s=773+r=001+l=a 10 Mistakes To Avoid When Seeking Venture Capital For Pharma/Bio <p>
Although generals from George Washington to Douglas MacArthur achieved great military success by focusing their forces on underdefended positions, the same does not hold true for venture capitalists. VCs are creatures of habit &mdash; actually, profitable habit. <i>By Rob Jevon</i></p>
Fri, 18 Sep 2009 05:18:00 GMThttps://www.lifescienceleader.com/doc/technology-roundtable-edc-electronic-data-0001?atc~c=771+s=773+r=001+l=a Technology Roundtable: EDC (Electronic Data Capture) <p>
How Do You Define EDC? Does It Start With An eCRF, Or Can It Start With A Physical CRF? <i>By Dan Schell, <u>Life Science Leader</u> magazine</i></p>
Wed, 14 Oct 2009 00:11:00 GMTDanSchell